Table 3 Univariate survival analyses

Gender

Females

(ref)

(ref)

0.03

Males

0.65

0.43–0.96

0.03

0.64

0.43–0.94

Age

Per 1 year increase

0.99

0.97–1.02

0.63

0.98

0.96–1.01

0.16

WHO PS

0

0.84

0.57–1.24

0.38

0.59

0.39–0.88

0.009

1–2

(ref)

(ref)

unknown^a

Location primary tumor

Right

0.74

0.45–1.23

0.25

1.21

0.72–2.02

0.48

Left

0.87

0.57–1.35

0.54

1.14

0.74–1.76

0.55

Rectum

(ref)

(ref)

Primary tumor resected

Yes

0.78

0.41–1.51

0.46

0.78

0.40–1.50

0.49

No

(ref)

(ref)

Number of metastatic sites

1

(ref)

(ref)

2

1.05

0.66–1.67

0.84

1.31

0.82–2.10

0.27

>2

1.23

0.77–1.96

0.40

1.51

0.95–2.40

0.09

Prior chemotherapy

F

(ref)

(ref)

F + Oxa

0.99

0.52–1.92

0.99

2.50

1.25–5.00

0.009

F + Oxa + Bev

1.91

0.52–6.96

0.33

3.53

0.94–13.2

0.06

Prior radiotherapy

Yes

0.71

0.29–1.75

0.46

0.85

0.35–2.10

0.73

No

(ref)

(ref)

Liver metastases

Yes

0.88

0.57–1.37

0.58

1.18

0.76–1.82

0.64

No

(ref)

(ref)

Lung metastases

Yes

1.09

0.73–1.61

0.67

1.50

1.01–2.21

0.044

No

(ref)

(ref)

TOP1 CN (CEN-20)

Per 1 unit increase

0.99

0.90–1.10

0.88

0.98

0.89–1.08

0.72

TOP1 CN (CEN-20)

>median (4.46)

0.95

0.65–1.40

0.79

0.92

0.62–1.35

0.66

≤ median (4,46)

(ref)

(ref)

TOP1/CEN-20 ratio

Per 1 unit increase

0.99

0.56–1.74

0.97

1.02

0.61–1.70

0.95

TOP1/CEN-2 ratio

Per 1 unit increase

1.10

0.85–1.35

0.58

1.00

0.79–1.27

0.98

TOP1/CEN-20 ratio

<1.5 (ref)

≥1.5

0.73

0.47–1.13

0.16

0.75

0.48–1.17

0.21